Joseph E. Oesterling

21.1k total citations · 7 hit papers
219 papers, 16.4k citations indexed

About

Joseph E. Oesterling is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Urology. According to data from OpenAlex, Joseph E. Oesterling has authored 219 papers receiving a total of 16.4k indexed citations (citations by other indexed papers that have themselves been cited), including 161 papers in Pulmonary and Respiratory Medicine, 77 papers in Rheumatology and 67 papers in Urology. Recurrent topics in Joseph E. Oesterling's work include Prostate Cancer Diagnosis and Treatment (136 papers), Prostate Cancer Treatment and Research (105 papers) and Urologic and reproductive health conditions (58 papers). Joseph E. Oesterling is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (136 papers), Prostate Cancer Treatment and Research (105 papers) and Urologic and reproductive health conditions (58 papers). Joseph E. Oesterling collaborates with scholars based in United States, Sweden and Finland. Joseph E. Oesterling's co-authors include Steven J. Jacobsen, Erik J. Bergstralh, Patrick C. Walsh, Alan W. Partin, Robert P. Myers, Jonathan I. Epstein, David G. Bostwick, Horst Zincke, Cynthia J. Girman and Laurel A. Panser and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Joseph E. Oesterling

217 papers receiving 15.3k citations

Hit Papers

Prostate Specific Antigen: A Critical Assessment of the M... 1988 2026 2000 2013 1991 1993 1993 1993 1994 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate
    1991 1.1k citations Joseph E. Oesterling profile →
  2. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges
    1993 914 citations Joseph E. Oesterling profile →
  3. Serum Prostate-Specific Antigen in a Community-Based Population of Healthy Men
    1993 620 citations Joseph E. Oesterling profile →
  4. The prevalence of Prostatism: A Population-Based Survey of Urinary Symptoms
    1993 620 citations Christopher G. Chute, Laurel A. Panser et al. profile →
  5. Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer
    1994 531 citations Horst Zincke, Joseph E. Oesterling et al. profile →
  6. Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign Hyperplasia
    1990 506 citations Jonathan I. Epstein, Joseph E. Oesterling et al. profile →
  7. Prostate Specific Antigen in the Preoperative and Postoperative Evaluation of Localized Prostatic Cancer Treated with Radical Prostatectomy
    1988 477 citations Joseph E. Oesterling, Jonathan I. Epstein et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joseph E. Oesterling United States 68 12.5k 5.2k 4.3k 2.6k 1.7k 219 16.4k
Peter C. Albertsen United States 62 11.3k 0.9× 2.4k 0.5× 2.5k 0.6× 3.3k 1.2× 3.8k 2.2× 241 16.1k
Giorgio Guazzoni Italy 59 7.0k 0.6× 3.3k 0.6× 4.5k 1.0× 4.9k 1.9× 864 0.5× 401 12.8k
Carl A. Olsson United States 52 5.5k 0.4× 2.2k 0.4× 2.0k 0.5× 2.3k 0.9× 1.4k 0.8× 236 9.8k
Fritz H. Schröder Netherlands 79 17.5k 1.4× 3.4k 0.6× 1.8k 0.4× 4.2k 1.6× 4.3k 2.5× 501 22.7k
James A. Eastham United States 87 21.8k 1.7× 6.6k 1.3× 2.9k 0.7× 6.0k 2.3× 4.3k 2.5× 538 27.3k
Alexandre de la Taille France 68 10.8k 0.9× 2.4k 0.5× 2.4k 0.5× 3.7k 1.4× 1.9k 1.1× 471 15.7k
Hartwig Huland Germany 73 11.7k 0.9× 3.4k 0.7× 2.0k 0.5× 4.2k 1.6× 2.8k 1.6× 613 17.5k
Axel Heidenreich Germany 65 14.0k 1.1× 4.3k 0.8× 1.8k 0.4× 7.2k 2.7× 3.6k 2.1× 716 21.5k
Yoichi Arai Japan 51 4.3k 0.3× 1.6k 0.3× 2.2k 0.5× 3.3k 1.3× 1.1k 0.6× 525 10.3k
Michael S. Cookson United States 68 7.1k 0.6× 1.9k 0.4× 3.6k 0.8× 7.5k 2.9× 2.2k 1.3× 310 14.7k

Countries citing papers authored by Joseph E. Oesterling

Since Specialization
Citations

This map shows the geographic impact of Joseph E. Oesterling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph E. Oesterling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph E. Oesterling more than expected).

Fields of papers citing papers by Joseph E. Oesterling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph E. Oesterling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph E. Oesterling. The network helps show where Joseph E. Oesterling may publish in the future.

Co-authorship network of co-authors of Joseph E. Oesterling

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph E. Oesterling. A scholar is included among the top collaborators of Joseph E. Oesterling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph E. Oesterling. Joseph E. Oesterling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oesterling, Joseph E., Johnny Roy, Torben Krarup, et al.. (1998). Biologic Variability of Prostate-Specific Antigen and its Usefulness as a Marker for Prostate Cancer: Effects of Finasteride. Urology. 51(4). 58–63. 9 indexed citations
2.
Jacobsen, Steven J., Erik J. Bergstralh, Slavica K. Katusic, et al.. (1998). Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology. 52(2). 173–179. 51 indexed citations
3.
Oesterling, Joseph E., et al.. (1998). Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing. Urology. 51(5). 98–109. 21 indexed citations
4.
Oesterling, Joseph E., et al.. (1998). Alpha-Blockade Therapy for Benign Prostatic Hyperplasia: from a Nonselective to a More Selective Alpha1A-Adrenergic Antagonist. Urology. 51(6). 861–872. 68 indexed citations
5.
Oesterling, Joseph E., Johnny Roy, Torben Krarup, et al.. (1997). Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: Effects of finasteride. Urology. 50(1). 13–18. 43 indexed citations
6.
Tchetgen, Marie‐Blanche & Joseph E. Oesterling. (1997). THE EFFECT OF PROSTATITIS, URINARY RETENTION, EJACULATION, AND AMBULATION ON THE SERUM PROSTATE-SPECIFIC ANTIGEN CONCENTRATION. Urologic Clinics of North America. 24(2). 283–291. 104 indexed citations
7.
Roehrborn, Claus G., Joseph E. Oesterling, Stephen M. Auerbach, et al.. (1996). The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology. 47(2). 159–168. 175 indexed citations
8.
Barry, Michael J., Craig Fleming, Christopher M. Coley, et al.. (1995). Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? part I: Framing the debate. Urology. 46(1). 2–13. 30 indexed citations
9.
Loprinzi, Charles L., John C. Michalak, Susan K. Quella, et al.. (1995). Megestrol Acetate for the Prevention of Hot Flashes. Obstetrical & Gynecological Survey. 50(2). 135–137. 6 indexed citations
10.
Jacobsen, Steven J., George G. Klee, Hans Lilja, George L. Wright, & Joseph E. Oesterling. (1995). Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. Urology. 45(3). 447–453. 26 indexed citations
11.
Panser, Laurel A., Christopher G. Chute, Harry A. Guess, et al.. (1994). The Natural History of Prostatism: The Effects of Non-Response Bias. International Journal of Epidemiology. 23(6). 1198–1205. 80 indexed citations
12.
Oesterling, Joseph E., Alfred J. Defalco, Steven A. Kaplan, et al.. (1994). The North American experience with the urolume endoprosthesis as a treatment for benign prostatic hyperplasia: Long-term results. Urology. 44(3). 353–362. 63 indexed citations
13.
14.
Messick, Joseph M., Joseph E. Oesterling, David E. Byer, et al.. (1992). A Prospective Randomized Comparison of Epidural Infusion of Fentanyl and Intravenous Administration of Morphine by Patient-Controlled Analgesia After Radical Retropubic Prostatectomy. Mayo Clinic Proceedings. 67(11). 1031–1041. 10 indexed citations
15.
Oesterling, Joseph E.. (1991). Introduction and editorial comment. Urology. 38(1). 2–3. 1 indexed citations
16.
Oesterling, Joseph E.. (1991). A Permanent, Epithelializing Stent for the Treatment of Benign Prostatic Hyperplasia Preliminary Results. Journal of Andrology. 12(6). 423–428. 18 indexed citations
17.
Oesterling, Joseph E.. (1991). The Origin and Development of Benign Prostatic Hyperplasia An Age‐Dependent Process. Journal of Andrology. 12(6). 348–355. 26 indexed citations
18.
Bilhartz, David L., Donald J. Tindall, & Joseph E. Oesterling. (1991). Prostate-specific antigen and prosttic acid phosphatase: Biomolecular and physiologic characteristics. Urology. 38(2). 95–102. 33 indexed citations
19.
Oesterling, Joseph E., Charles B. Brendler, John K. Burgers, Fray F. Marshall, & Jonathan I. Epstein. (1990). Advanced small cell carcinoma of the bladder successful treatment with combined radical cystoprostatectomy and adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer. 65(9). 1928–1936. 59 indexed citations
20.
Bohlman, Mark E., Elliot K. Fishman, Joseph E. Oesterling, & Stanford M. Goldman. (1988). Case profile: CT findings in emphysematous cystitis. Urology. 32(1). 63–64. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter C. Albertsen Breakdown of academic impact, for papers by Giorgio Guazzoni Breakdown of academic impact, for papers by Carl A. Olsson Breakdown of academic impact, for papers by Fritz H. Schröder Breakdown of academic impact, for papers by James A. Eastham Breakdown of academic impact, for papers by Alexandre de la Taille Breakdown of academic impact, for papers by Hartwig Huland Breakdown of academic impact, for papers by Axel Heidenreich Breakdown of academic impact, for papers by Yoichi Arai Breakdown of academic impact, for papers by Michael S. Cookson
Rankless by CCL
2026